CRVS earnings: a positive outcome, +6.6%

On November 1, 2021, Corvus Pharmaceuticals, Inc. reached its earnings. The result was a positive outcome, and the stock moved +6.6% in the window around the event. It had already run -5.8% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.